Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1975 3
1976 5
1977 2
1979 1
1980 10
1981 8
1982 8
1983 10
1984 8
1985 11
1986 13
1987 18
1988 13
1989 24
1990 20
1991 17
1992 25
1993 27
1994 27
1995 26
1996 39
1997 39
1998 39
1999 42
2000 34
2001 48
2002 44
2003 50
2004 55
2005 66
2006 75
2007 56
2008 102
2009 100
2010 103
2011 114
2012 121
2013 145
2014 172
2015 166
2016 150
2017 161
2018 139
2019 163
2020 177
2021 165
2022 159
2023 121
2024 116

Text availability

Article attribute

Article type

Publication date

Search Results

2,892 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Breast Carcinoma Metastatic in the Lung"
Page 1
Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps.
Park J, Wysocki RW, Amoozgar Z, Maiorino L, Fein MR, Jorns J, Schott AF, Kinugasa-Katayama Y, Lee Y, Won NH, Nakasone ES, Hearn SA, Küttner V, Qiu J, Almeida AS, Perurena N, Kessenbrock K, Goldberg MS, Egeblad M. Park J, et al. Sci Transl Med. 2016 Oct 19;8(361):361ra138. doi: 10.1126/scitranslmed.aag1711. Sci Transl Med. 2016. PMID: 27798263 Free PMC article.
NETs produced by infection can promote cancer metastasis. We show that metastatic breast cancer cells can induce neutrophils to form metastasis-supporting NETs in the absence of infection. Using intravital imaging, we observed NET-like structures around me …
NETs produced by infection can promote cancer metastasis. We show that metastatic breast cancer cells can induce neutrophils t …
Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives.
Medeiros B, Allan AL. Medeiros B, et al. Int J Mol Sci. 2019 May 8;20(9):2272. doi: 10.3390/ijms20092272. Int J Mol Sci. 2019. PMID: 31071959 Free PMC article. Review.
Breast cancer spreads preferentially to the lung, brain, bone and liver; termed organ tropism. Current treatment methods for metastatic breast cancer have been ineffective, compounded by the lack of early prognostic/predictive methods to determi …
Breast cancer spreads preferentially to the lung, brain, bone and liver; termed organ tropism. Current treatment methods for …
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Tsai CJ, et al. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104577 Clinical Trial.
METHODS: We did a phase 2, open-label, randomised controlled trial of SBRT in patients with oligoprogressive metastatic breast cancer or non-small-cell lung cancer (NSCLC) after having received at least first-line systemic therapy, with oligoprogression defin …
METHODS: We did a phase 2, open-label, randomised controlled trial of SBRT in patients with oligoprogressive metastatic breast …
The temporal progression of lung immune remodeling during breast cancer metastasis.
McGinnis CS, Miao Z, Superville D, Yao W, Goga A, Reticker-Flynn NE, Winkler J, Satpathy AT. McGinnis CS, et al. Cancer Cell. 2024 Jun 10;42(6):1018-1031.e6. doi: 10.1016/j.ccell.2024.05.004. Epub 2024 May 30. Cancer Cell. 2024. PMID: 38821060
However, our understanding of immune phenotypic dynamics in the metastatic niche remains incomplete. Here, we longitudinally assayed lung immune transcriptional profiles in the polyomavirus middle T antigen (PyMT) and 4T1 metastatic breast cancer model …
However, our understanding of immune phenotypic dynamics in the metastatic niche remains incomplete. Here, we longitudinally assayed …
Nicotine promotes breast cancer metastasis by stimulating N2 neutrophils and generating pre-metastatic niche in lung.
Tyagi A, Sharma S, Wu K, Wu SY, Xing F, Liu Y, Zhao D, Deshpande RP, D'Agostino RB Jr, Watabe K. Tyagi A, et al. Nat Commun. 2021 Jan 20;12(1):474. doi: 10.1038/s41467-020-20733-9. Nat Commun. 2021. PMID: 33473115 Free PMC article.
Elevated levels of serum and urine LCN2 is elevated in early-stage breast cancer patients and cancer-free females with smoking history, suggesting that LCN2 serve as a promising prognostic biomarker for predicting increased risk of metastatic disease in femal …
Elevated levels of serum and urine LCN2 is elevated in early-stage breast cancer patients and cancer-free females with smoking histor …
Metastatic behavior of breast cancer subtypes.
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Kennecke H, et al. J Clin Oncol. 2010 Jul 10;28(20):3271-7. doi: 10.1200/JCO.2009.25.9820. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498394
PURPOSE: Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected. ...TN nonbasal tumors demonstrated a similar pattern but were not associated with fewer liver metast …
PURPOSE: Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which …
Characterizing Macrophage Diversity in Metastasis-Bearing Lungs Reveals a Lipid-Associated Macrophage Subset.
Huggins DN, LaRue RS, Wang Y, Knutson TP, Xu Y, Williams JW, Schwertfeger KL. Huggins DN, et al. Cancer Res. 2021 Oct 15;81(20):5284-5295. doi: 10.1158/0008-5472.CAN-21-0101. Epub 2021 Aug 13. Cancer Res. 2021. PMID: 34389631 Free PMC article.
While macrophages are among the most abundant immune cell type found within primary and metastatic mammary tumors, how their complexity and heterogeneity change with metastatic progression remains unknown. ...Enrichment of genes implicated in pathways related to lip …
While macrophages are among the most abundant immune cell type found within primary and metastatic mammary tumors, how their complexi …
Health state utilities for non small cell lung cancer.
Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Nafees B, et al. Health Qual Life Outcomes. 2008 Oct 21;6:84. doi: 10.1186/1477-7525-6-84. Health Qual Life Outcomes. 2008. PMID: 18939982 Free PMC article.
BACKGROUND: Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. ...METHODS: Existing health state descriptions of metastatic breast cancer wer …
BACKGROUND: Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not …
Immunotherapy for metastatic breast cancer.
Sugie T. Sugie T. Chin Clin Oncol. 2018 Jun;7(3):28. doi: 10.21037/cco.2018.05.05. Chin Clin Oncol. 2018. PMID: 30056730 Free article. Review.
Blocking antibodies against programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) leads to robust local tumor control and a durable response in patients with various tumors that are refractory to standard treatments. Breast cancer was traditionally thought to be poor …
Blocking antibodies against programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) leads to robust local tumor control and a durable re …
Metastatic Neoplasms to the Breast.
Özşen M, Tolunay S, Polatkan SAV, Senol K, Gokgoz MS. Özşen M, et al. Int J Surg Pathol. 2024 Aug;32(5):875-883. doi: 10.1177/10668969231201415. Epub 2023 Oct 29. Int J Surg Pathol. 2024. PMID: 37899598 Free PMC article.
In this study, it is aimed to present our cases of non-hematopoietic metastatic neoplasms and to evaluate the clinicopathological features that may aid in distinguishing metastatic from primary neoplasms. MATERIAL AND METHODS: This study includes cases …
In this study, it is aimed to present our cases of non-hematopoietic metastatic neoplasms and to evaluate the clinicopathologi …
2,892 results